ETHNOPHARMACOLOGICAL APPROACH OF HEDERAGENIN ATED FROM SAPINDUS TRIFOLIATUS L. ON NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) ASSOCIATED WITH TYPE 2 DIABETES IN C57BL/6 MICE

Vinitha Lakshmi*, Dhamotharan. R, Kalyan kumar. G

ABSTRACT

Ethnopharmacological relevance: Hederagenin, a saponin extracted from fruits of Sapindus trifoliatus is used as astringent, thermogenic, anti-inflammatory, analgesic, antifungal, antiviral, anti helmintic and tonic in action. NAFLD is a liver disorder characterised by fat accumulation and is treated only at the advanced stages of cirhossis. The cure of it still remains untold. Whereas the current approach with traditional medicine has found it successful in reducing the liver enlargement and removes the accumulated fat indicating the right choice of medicine for NAFLD. Aim of the study: The present study investigated the activity of Hederagenin on non alcoholic fatty liver disease (NAFLD) associated with type 2 diabetes in murine model which is a novel approach. Materials and methods: Male C57BL/6 mice (6–8 weeks of age) were fed with high fat diet for eight weeks and then dosed with Hederagenin at doses of 100, 300 and 500 mg/kg p.o., metformin for 350mg/kg p.o. Normal control animals were fed with normal standard pellet diet whereas the positive control group along with treatment group still maintained the high fat diet. At the end of the experimental period, the final body weight and feed intake were taken and whole blood was collected by retro orbital sinus punctures. Plasma/serum was obtained by cold centrifugation (4°C) till analysis. Later animals were sacrificed by cervical dislocation and, liver were excised and stored at - 80°C. Results: Hederagenin significantly suppressed lipid accumulation in the liver, reduced biochemical, insulin resistance, and lipid in HFD-fed C57BL/6 mice. These findings may provide molecular evidence for the use of Hederagenin as a therapy in the management of fatty liver and obesity-relative disorders. Conclusion: These findings may exhibited the use of Hederagenin as a therapy in the management of fatty liver and obesity-relative disorders.

Keywords: NAFLD, NASH, Hederagenin, C57BL/6 mice, HFD fed mice, Type 2 diabetes.